March 31, 2022 | Cogstate, Decentralized trials, Impetus Digital, Natalie Yeadon, Pam Ventola, brain health, central rating, central scoring, clinical insights, clinical trials, cognitive testing, digital assessments, rare disease
Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can help advance the development of new medicines and enable earlier clinical insights. She also discusses cognitive testing as part of decentralized trials, the role of central rating and central scoring, the development of indication-specific COAs for rare disease trials, and much more.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Stephany Lapierre, Founder and CEO of Tealbook sits down with us in this Fireside Chat. Stephany is a highly coveted supply chain thought-leader, and one of the most influential minds in…
Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,…
In this session, we discussed systems change, wicked problems, and multisolving. We reviewed the transformational changes that can evolve and go beyond “cause and effect” thinking. In this dialogue, we…
Find out how Impetus Digital helped virtualize their client’s internal brand planning session
Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work and…
Ladana Edwards, Partner at Deloitte Central Europe and Thomas de Bruyne, Consultant with Deloitte Belgium, share their thoughts on the future of education and the role of digital technologies such as virtual…
A holistic view of how to work with patients virtually
